Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Canine adenovirus type 2 (CAV-2) capsid antigens are the structural proteins—primarily hexon, penton base, and fiber—that constitute the outer shell of the virus. These proteins play a fundamental role in the viral infection cycle; the fiber protein mediates high-affinity binding to the host's coxsackievirus and adenovirus receptor (CAR), while the penton base facilitates internalization via integrin interactions. In clinical practice, these antigens are the primary targets for veterinary vaccines, where they serve as immunogens to elicit neutralizing antibodies that prevent respiratory infections known as infectious tracheobronchitis or "kennel cough". Unlike CAV-1, which causes systemic hepatitis, CAV-2 is localized to the respiratory tract, making its capsid antigens safer for use in modified-live vaccines to provide cross-protection against both viral strains without the risk of "blue eye" (corneal edema). Furthermore, the unique tropism of the CAV-2 capsid for neuronal cells has led to its development as a potent vector for gene therapy in the central nervous system. Therapeutic intervention typically focuses on the induction of a robust immune response through vaccination, where the capsid antigens act as the target for neutralizing antibodies that prevent viral infection.
Induction of active immunity through the production of neutralizing antibodies that target viral capsid proteins to prevent host cell attachment and entry.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Canine adenovirus type 2 capsid protein (CAV-2 capsid antigens).